|
Exposure-response (E-R) efficacy and safety (E-S) analyses of tremelimumab as monotherapy or in combination with durvalumab in patients (pts) with unresectable hepatocellular carcinoma (uHCC). |
|
|
|
|
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst) |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Ipsen |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Employment - Shanghai Qiangshi Information Technology |
Consulting or Advisory Role - AstraZeneca |
|
|
Employment - Shanghai Qiangshi Information Technology |
Consulting or Advisory Role - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - Abbvie |
Travel, Accommodations, Expenses - Certara Inc |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva |
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst) |
Travel, Accommodations, Expenses - Polaris |